Australia
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.46 (0.33 - 0.62) | 2015 | Modelled | WHO |
1 (0.90 - 1) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
0.9 | 2018 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2020 |
0.37 (0.36 - 0.38) | 2013 | Modelled | Schweitzer et al, 2015 |
1.01 | 2015 | Modelled | Maclachlan et al, 2018 |
2.14 (1.94 - 2.34) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
2.46 (2.20 - 2.68) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.5 (2.20 - 2.82) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.51 (2.25 - 2.79) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.52 (2.25 - 2.79) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.53 (2.27 - 2.79) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.57 (2.33 - 2.82) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.61 (2.38 - 2.86) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.65 (2.41 - 2.90) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.67 (2.43 - 2.93) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.68 (2.45 - 2.93) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.72 (2.48 - 2.96) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.77 (2.51 - 3) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.8 (2.55 - 3.04) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.82 (2.55 - 3.08) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.83 (2.57 - 3.07) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.85 (2.60 - 3.10) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.88 (2.62 - 3.13) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.91 (2.64 - 3.18) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.92 (2.65 - 3.21) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.94 (2.68 - 3.21) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.97 (2.71 - 3.25) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.01 (2.75 - 3.28) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.04 (2.76 - 3.33) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.06 (2.77 - 3.37) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.07 (2.79 - 3.36) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.07 (2.80 - 3.37) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.08 (2.82 - 3.38) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.08 (2.82 - 3.40) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.08 (2.79 - 3.42) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.38 (2.15 - 2.60) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.15 (0.09 - 0.23) | 2015 | Modelled | WHO |
0.4 (0 - 2.20) | 2002 | Survey/reported | WHO WPRO, Woodring J et al, 2017 |
0.07 (0.06 - 0.09) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.11 (0.09 - 0.14) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.11 (0.09 - 0.14) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.11 (0.09 - 0.14) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.12 (0.09 - 0.15) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.10 - 0.16) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.10 - 0.17) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.10 - 0.17) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.10 - 0.17) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.11 - 0.17) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.10 - 0.17) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.11 - 0.17) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.11 - 0.17) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.11 - 0.17) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.14 (0.11 - 0.17) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.14 (0.11 - 0.17) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.14 (0.11 - 0.17) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.14 (0.11 - 0.18) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.12 - 0.19) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.16 (0.13 - 0.20) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.18 (0.14 - 0.23) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.31 (0.24 - 0.40) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.47 - 0.77) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.96 (0.75 - 1.21) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.26 (0.97 - 1.60) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.4 (1.08 - 1.78) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.41 (1.10 - 1.79) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.41 (1.10 - 1.78) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.39 (1.10 - 1.77) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.37 (1.07 - 1.76) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.34 (1.04 - 1.74) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.11 - 0.16) | 2020 | Modelled | WHO |
Showing out of
Show more
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
3.7 | 2018 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2024 |
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
2.8 | 2018 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2022 |
Aboriginal and/or Torres Strait Islander people
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
2 | 2018 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2023 |
People born overseas
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.9 | 2018 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2025 |
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
234,000 (222,000 - 252,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
226,566 | 2018 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2021 |
233,947 (222,706 - 246,015) | 2017 | Survey/reported | The Kirby Institute, 2018 |
230,034 (219,465 - 249,457) | 2016 | Survey/reported | The Kirby Institute, 2017 |
525,919 (477,108 - 573,902) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
546,429 (494,974 - 596,405) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
561,837 (503,865 - 612,992) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
564,609 (496,769 - 638,444) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
557,618 (499,962 - 621,592) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
550,652 (490,683 - 611,628) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
545,446 (490,243 - 602,298) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
544,061 (493,527 - 596,074) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
543,947 (495,574 - 595,610) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
542,567 (493,449 - 595,647) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
537,454 (489,645 - 591,697) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
532,589 (485,911 - 582,138) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
531,917 (484,708 - 578,038) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
532,761 (484,908 - 578,243) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
532,355 (483,447 - 577,654) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
528,200 (477,298 - 576,203) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
523,653 (475,185 - 569,401) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
522,333 (475,289 - 566,685) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
522,313 (476,064 - 567,325) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
521,643 (474,899 - 569,565) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
518,395 (470,252 - 567,996) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
514,723 (469,008 - 561,889) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
513,053 (468,281 - 560,023) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
512,184 (467,103 - 557,984) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
510,810 (462,406 - 559,299) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
507,664 (457,113 - 555,855) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
503,478 (456,882 - 551,601) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
499,388 (456,008 - 547,929) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
495,130 (454,063 - 543,191) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
490,520 (448,342 - 540,557) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
485,428 (439,651 - 538,037) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
2.19 (1.74 - 2.74) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
1.98 (1.55 - 2.47) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
2 (1.57 - 2.49) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.05 (1.62 - 2.55) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.08 (1.64 - 2.57) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.14 (1.69 - 2.65) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.15 (1.71 - 2.65) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.19 (1.74 - 2.69) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.21 (1.76 - 2.71) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.19 (1.77 - 2.69) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.19 (1.76 - 2.70) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.22 (1.78 - 2.72) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.35 (1.89 - 2.87) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.26 (1.81 - 2.77) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.42 (1.94 - 2.95) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.46 (1.98 - 2.98) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.46 (1.99 - 2.97) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.5 (2.01 - 3.01) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.36 (1.90 - 2.87) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.21 (1.77 - 2.73) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.02 (1.60 - 2.52) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.06 (1.64 - 2.56) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.07 (1.64 - 2.58) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.09 (1.66 - 2.62) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.23 (1.77 - 2.80) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.16 (1.72 - 2.71) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.27 (1.80 - 2.85) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.22 (1.76 - 2.78) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.18 (1.74 - 2.74) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.18 (1.74 - 2.73) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.19 (1.74 - 2.74) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,634 | 2016 | Modelled | WHO |
333 (262 - 417) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
342 (269 - 426) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
355 (280 - 441) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
364 (288 - 450) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
379 (299 - 468) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
385 (306 - 474) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
396 (315 - 487) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
403 (321 - 495) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
405 (326 - 496) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
410 (329 - 503) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
418 (336 - 513) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
455 (365 - 554) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
432 (346 - 529) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
487 (392 - 591) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
475 (380 - 578) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
501 (403 - 605) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
488 (392 - 594) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
501 (405 - 605) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
439 (348 - 544) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
464 (370 - 572) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
454 (360 - 566) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
436 (345 - 544) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
466 (369 - 583) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
489 (388 - 613) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
523 (417 - 656) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
527 (419 - 662) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
512 (407 - 641) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
522 (416 - 655) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
530 (422 - 663) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
537 (427 - 674) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
537 (427 - 674) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
94.7 | 2018 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2027 |
95 | 2019 | Survey/reported | WHO/UNICEF |
95 | 2020 | Survey/reported | WHO/UNICEF |
95 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
461 (364 - 631) | 2016 | Survey/reported | Iversen J et al, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
41.8 (39.80 - 43.90) | 2015 | Survey/reported | Memedovic S et al, 2016 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.78 | 2016 | Survey/reported | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2028 |
0.74 (0.52 - 0.78) | 2017 | Survey/reported | The Kirby Institute, 2018 |
1 (0.70 - 1) | 2015 | Modelled | Blach et al, 2017 |
1.62 (1.27 - 2.04) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.6 (1.27 - 2) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.6 (1.26 - 2.01) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.62 (1.29 - 2.01) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.65 (1.31 - 2.05) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.65 (1.33 - 2.07) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.67 (1.34 - 2.08) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.68 (1.35 - 2.09) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.69 (1.36 - 2.11) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.69 (1.36 - 2.11) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.69 (1.36 - 2.11) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.67 (1.35 - 2.10) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.65 (1.33 - 2.08) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.63 (1.30 - 2.06) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.62 (1.28 - 2.07) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.63 (1.29 - 2.05) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.63 (1.32 - 2.05) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.65 (1.34 - 2.05) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.67 (1.36 - 2.06) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.68 (1.38 - 2.07) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.71 (1.40 - 2.09) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.75 (1.44 - 2.12) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.79 (1.47 - 2.15) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.81 (1.49 - 2.18) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.82 (1.49 - 2.20) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.81 (1.49 - 2.18) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.8 (1.48 - 2.17) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.78 (1.46 - 2.16) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.75 (1.43 - 2.13) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.71 (1.39 - 2.12) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.5 (1.18 - 1.90) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
51 | 2016 | Survey/reported | The Kirby Institute, 2017 |
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.54 (0.41 - 0.57) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.3 | 2019 | Modelled | Jin et al. 2017 |
1.7 (1.20 - 1.80) | 2014 | Modelled | Gower et al, 2014 |
Showing out of
Show more
Men who have sex with men (MSM) Living with HIV
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
8.7 (7.60 - 9.90) | 2019 | Modelled | Jin et al. 2017 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
53.5 (50.20 - 56.90) | 2014 | Modelled | Degenhardt L et al, 2017 |
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
2.8 | 2019 | Modelled | Jin et al. 2017 |
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
230,000 (178,000 - 244,000) | 2015 | Modelled | Blach et al, 2017 |
199,412 (145,585 - 210,403) | 2016 | Survey/reported | The Kirby Institute, 2017 |
182,144 (128,845 - 192,981) | 2017 | Survey/reported | The Kirby Institute, 2018 |
269,362 (218,617 - 331,892) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
278,293 (227,926 - 339,152) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
285,875 (235,413 - 346,852) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
292,220 (241,475 - 351,849) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
297,523 (244,452 - 358,063) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
302,022 (246,961 - 363,691) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
304,421 (251,389 - 366,991) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
303,865 (250,657 - 366,896) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
301,719 (249,086 - 366,041) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
299,513 (245,816 - 366,392) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
298,793 (243,663 - 367,777) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
299,050 (244,372 - 369,638) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
298,924 (242,764 - 371,278) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
299,164 (240,964 - 377,103) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
300,592 (238,960 - 379,013) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
303,998 (240,341 - 386,810) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
310,097 (246,813 - 392,570) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
318,026 (256,521 - 402,131) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
326,638 (263,934 - 413,361) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
334,888 (269,383 - 419,136) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
341,434 (273,120 - 426,014) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
346,084 (277,332 - 431,972) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
349,895 (281,331 - 436,096) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
353,067 (282,818 - 440,695) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
356,123 (285,531 - 446,046) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
359,707 (286,907 - 449,105) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
359,807 (286,998 - 447,064) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
360,402 (285,344 - 453,482) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
365,598 (289,446 - 457,318) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
368,380 (288,926 - 466,027) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
371,124 (291,406 - 468,733) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
31,500 (24,300 - 33,400) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
6.37 (5.29 - 7.31) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
4.12 (3.49 - 4.71) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.08 (3.46 - 4.66) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.1 (3.49 - 4.67) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.1 (3.47 - 4.68) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.18 (3.53 - 4.76) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.18 (3.54 - 4.77) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.24 (3.58 - 4.84) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.26 (3.60 - 4.84) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.23 (3.58 - 4.80) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.25 (3.59 - 4.84) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.28 (3.61 - 4.90) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.51 (3.79 - 5.16) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.36 (3.67 - 4.99) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.61 (3.87 - 5.26) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.65 (3.92 - 5.32) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.71 (3.97 - 5.40) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.82 (4.04 - 5.51) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.28 (4.40 - 6.03) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.04 (4.23 - 5.77) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.43 (4.55 - 6.22) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.59 (4.69 - 6.42) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.84 (4.93 - 6.69) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.75 (4.85 - 6.60) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.05 (5.12 - 6.92) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.4 (5.41 - 7.36) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.26 (5.27 - 7.18) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.38 (5.33 - 7.29) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.34 (5.31 - 7.27) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.4 (5.34 - 7.35) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
6.37 (5.29 - 7.31) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
335 | 2016 | Modelled | WHO |
621 | 2016 | Survey/reported | Australia Fifth National Hepatitis C Strategy 2018-2022 |
1,564 (1,301 - 1,797) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,564 (1,301 - 1,797) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
1,552 (1,295 - 1,784) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,519 (1,271 - 1,740) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,506 (1,258 - 1,722) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,491 (1,259 - 1,713) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,437 (1,209 - 1,648) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,368 (1,157 - 1,565) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,301 (1,097 - 1,490) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,260 (1,063 - 1,446) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,206 (1,013 - 1,386) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,156 (968 - 1,323) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,106 (923 - 1,264) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,041 (874 - 1,192) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
981 (824 - 1,122) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
946 (798 - 1,084) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
921 (777 - 1,055) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
902 (758 - 1,029) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
872 (732 - 998) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
833 (701 - 953) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
809 (681 - 925) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
793 (670 - 904) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
780 (660 - 886) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
778 (657 - 885) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
767 (646 - 874) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
748 (632 - 854) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
740 (625 - 843) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
718 (608 - 820) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
709 (604 - 808) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
698 (591 - 796) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
695 (589 - 794) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of persons treated for HCV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
30,434 | 2016 | Survey/reported | The Kirby Institute, 2017 |
4,340 | 2015 | Survey/reported | The Kirby Institute, 2019 |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
461 (364 - 631) | 2016 | Survey/reported | Iversen J et al, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
41.8 (39.80 - 43.90) | 2015 | Survey/reported | Memedovic S et al, 2016 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
Overview
HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030
Prevalence (national)
Modelled
Survey/surveillance
No data available
Hepatitis related deaths (national)
Modelled
HBV
537
2019
(427 - 674)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
1,564
2019
(1,301 - 1,797)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
HCV
621
2016
Australia Fifth National Hepatitis C Strategy 2018-2022
HCV chart
Prevalence < 5
HBV
0.13
(%)
2020, latest modelled
(0.11 - 0.16(%))
WHO
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines